Fenwick represented Mozart Therapeutics, developer of CD8 Treg Modulators for the treatment of autoimmune and inflammatory diseases, in its $25 million additional financing, bringing its Series A round to $80 million. The round was led by ARCH Venture Partners with participation from new investors Pfizer Ventures, AbbVie Ventures, Ono Venture Investment and UPMC Enterprises.
Mozart Therapeutics will use the funds to advance the company's lead candidate, MTX-101, a bispecific autoimmune checkpoint inhibitor, into first-in-human clinical trials and to support pipeline expansion. More information can be obtained from the company's
The Fenwick transaction team was led by corporate partner Allison Cooper and associates Evan McCormick, Mike Kim and Michelle Le.